Clinical trials: Depressive State
Depression, Anxiety, Healthy
Voice Biomarkers Predictive of Depression and Anxiety
The objective of this study is to collect data to improve the sensitivity and specificity of Kintsugi Voice's (formerly KiVATM) predictions on audio files.
- Conditions
- Depression, Anxiety, Healthy, Mental Health Wellness 1
- Trial name
- NCT05455905
- Testing
- Patient Health Questionnaire-9, Generalized Anxiety Disorder-7, Hamilton Depression Rating Scale
- Where
- United States
- Volunteers
- 19,533 people
- Sponsor
- Kintsugi Mindful Wellness, Inc.
Generalized Anxiety Disorder
A Study To Assess Adverse Events and Change in Disease Activity With Oral Cariprazine When Added to Antidepressant Therapies (ADTs) Compared to Placebo in Adult Participants With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADTs Alone
Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately treat GAD.
- Trial name
- CAR aGAD Ph 2 (NCT04965272)
- Testing
- Cariprazine 0.75 mg/day, Cariprazine 1.5 mg/day, Cariprazine 3.0 mg/day
- Where
- 36 sites in United States
- Sponsor
- AbbVie
Treatment-resistant Depression (TRD)
ALTO-207 in Adults With Treatment-resistant Depression (TRD)
The purpose of this trial is to measure depressive symptoms following treatment with ALTO-207 compared with placebo in participants with TRD.
- Trial name
- NCT07553637
- Testing
- ALTO-207
- Where
- 63 sites in United States, United Kingdom
- Volunteers
- 178 people
- Sponsor
- Alto Neuroscience
Postpartum Depression
Pivotal Test: WB001
The purpose of the present randomized controlled study is to investigate if there is a difference in postpartum depression symptoms among participants assigned to : 1.
- Trial name
- NCT04576754
- Testing
- WB001, Educational
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- Woebot Health
Major Depressive Disorder (MDD)
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
This will be a multicenter, randomized, double-blind study designed to assess the efficacy, safety and tolerability of an oral Aripiprazole/Escitalopram combination therapy in participants with MDD who have demonstrated an…
- Trial name
- NCT01111539
- Testing
- Escitalopram, Aripiprazole, Blinded capsule
- Where
- 62 sites in United States, Estonia and 7 more
- Volunteers
- 211 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Treatment-Resistant Depression
Efficacy and Safety of TAK-653 in Treatment-Resistant Depression
The purpose of this study is to evaluate the efficacy of TAK-653 compared with placebo in maintaining the effect of ketamine treatment on depressive symptoms.
- Trial name
- NCT03312894
- Testing
- TAK-653
- Sponsor
- Millennium Pharmaceuticals, Inc.
Major Depressive Disorder
Major Depressive Disorder With Mixed Features - Extension
Lurasidone HCl is a compound that is a candidate for the treatment of major depressive with mixed features.This clinical study is designed to test how well Lurasidone works to treat major depressive disorder with mixed features…
- Trial name
- RESOLVE3 (NCT01423253)
- Testing
- Lurasidone
- Where
- 17 sites in United States
- Volunteers
- 48 people
- Sponsor
- Sumitomo Pharma America, Inc.
Depression
A Feasibility Study of an AI-Powered Clinical Decision Aid for Personalized Depression Treatment Selection
The Clinical Decision Aid (CDA) is a predictive model that takes as input individual patient characteristics, called 'features', which are inputted by the physician or by patient self-report, and outputs a list of possible…
- Trial name
- NCT04061642
- Testing
- Clinical Decision Aid
- Where
- Canada
- Volunteers
- 17 people
- Sponsor
- Aifred Health Inc.
Major Depressive Disorder
Safety Study of Escitalopram in Children 7 to 11 Years of Age With Major Depressive Disorder
This study will evaluate the long-term safety and tolerability of escitalopram (Lexapro) in children 7 to 11 years of age with major depressive disorder (MDD).
- Trial name
- NCT01198795
- Testing
- Escitalopram
- Where
- 16 sites in United States
- Volunteers
- 162 people
- Sponsor
- Forest Laboratories
Depression
Single Dose Study of BMS-820836
The purpose of this study is to determine the safety and tolerability of BMS-820836 after single doses
- Trial name
- NCT00964912
- Testing
- BMS-820836
- Where
- Canada
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Depression
Implementing IntelliCare in Collaborative Care: A Quality Improvement Evaluation
The overarching aim of the proposed project is to conduct a pragmatic, quality improvement evaluation of the IntelliCare Platform for improving processes of care in the Rush Collaborative Care program, and improving patient…
- Trial name
- NCT04499729
- Testing
- IntelliCare, Treatment as Usual (TAU)
- Where
- United States
- Volunteers
- 318 people
- Sponsor
- Adaptive Health, Inc
Non-psychotic Unipolar Major Depression
Prevalence and Risk Factors in Unipolar Depression Patients Without Remission After One Antidepressant Trial
A non interventional, descriptive, longitudinal cohort study is designed, trying to obtain local data about the prevalence of non remitted depressed patients after an antidepressant treatment, and to get information about…
- Trial name
- PANTHER (NCT01887639)
- Where
- 8 sites in Argentina
- Volunteers
- 200 people
- Sponsor
- AstraZeneca
Depressive Symptoms
Combination Therapy in Patients With Depression
The purpose of the study is to compare sertraline and atomoxetine/sertraline combination therapy in patients with persistent depressive symptoms.
- Trial name
- NCT00485862
- Testing
- Atomoxetine Hydrochloride, Sertraline
- Where
- United States
- Volunteers
- 214 people
- Sponsor
- Eli Lilly and Company
Depression, Postpartum, Postpartum Depression
A Study to Assess the Efficacy, Safety, and Tolerability of Oral NORA520 in Adults With Severe Postpartum Depression
The purpose of this research study is to test the study drug, NORA520, as a possible treatment for severe postpartum depression (PPD).
- Conditions
- Depression, Postpartum, Postpartum Depression, Post-partum Depression, Postnatal Depression
- Trial name
- NuMom (NCT06285916)
- Testing
- NORA520 Dose 1, NORA520 Dose 2
- Where
- 18 sites in United States
- Volunteers
- 93 people
- Sponsor
- TWi Biotechnology, Inc.
Major Depressive Disorder
Combination Deplin® and Antidepressant Therapy for a Major Depressive Episode (MDE)- a Retrospective Analysis
This is a retrospective chart review study to determine if Deplin® 7.5mg-15mg combined with an antidepressant is better than an antidepressant alone in adults with major depression.
- Trial name
- NCT01001559
- Testing
- L-methylfolate, Selective serotonin reuptake inhibitor (SSRI), Serotonin and norepinephrine reuptake inhibitor (SNRI)
- Where
- United States
- Volunteers
- 242 people
- Sponsor
- Pamlab, Inc.
Depression
Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Healthy Subjects
This study evaluates the safety, tolerability and pharmacokinetics of Ammoxetine Hydrochloride Enteric-coated Tablets in Chinese heathy subjects.
- Trial name
- NCT03456388
- Testing
- Ammoxetine Hydrochloride Enteric-coated Tablets
- Where
- China
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Depression, Major Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Child And Adolescent Outpatients With Major Depressive Disorder
The primary purpose of this study is to test the safety and tolerability of single ascending doses of Desvenlafaxine Succinate Sustained-Release (DVS SR) in both child and adolescent outpatients with major depressive disorder.
- Trial name
- NCT00619619
- Testing
- Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)
- Where
- 9 sites in United States
- Volunteers
- 59 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Depressive Disorder, Major
European Deep Brain Stimulation (DBS) Depression Study
To evaluate the effects of two different programming settings of deep brain stimulation (DBS) in the subgenual white matter (Brodmann Area 25 WM) as an adjunctive treatment for treatment resistant Major Depressive Disorder…
- Trial name
- NCT01331330
- Testing
- Deep Brain Stimulation
- Where
- 5 sites in France, Israel and 1 more
- Volunteers
- 9 people
- Sponsor
- Abbott Medical Devices
Bi-Polar Disorder, Autism Spectrum Disorder (ASD)
An Examination of the Performance of QbMobile in Differential Diagnosis Associated With ADHD Symptoms
The purpose of this study is to evaluate QbMobile's ability to collect objective data to identify specific symptom profiles in differential diagnoses (ASD, MDD, Bipolar Disorder and Anxiety Disorder) that are common with ADHD.
- Conditions
- Bi-Polar Disorder, Autism Spectrum Disorder (ASD), Major Depression Disorders, Separation Anxiety Disorder
- Trial name
- NCT07329673
- Testing
- Digital software application for cognitive performance and activity measurement (QbMobile, investigational device)
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Qbtech AB
Major Depressive Episode (MDE), Major Depressive Disorder (MDD)
A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
The goal of this clinical trial is to learn if a drug called TNX-102 SL works to treat moderate to severe major depressive disorder in adults. It will also learn about the safety of TNX-102 SL.
- Conditions
- Major Depressive Episode (MDE), Major Depressive Disorder (MDD), Depression
- Trial name
- HORIZON (NCT07621237)
- Testing
- TNX-102 SL
- Where
- 27 sites in United States
- Volunteers
- 360 people
- Sponsor
- Tonix Pharmaceuticals, Inc.